• Out-of-Stock

TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay
Sorry, This item is out of stock.

  Security policy

(edit with the Customer Reassurance module)

  Delivery policy

(edit with the Customer Reassurance module)

  Return policy

(edit with the Customer Reassurance module)

Product Highlights

TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.


Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.

This TruSight Tumor panel offers:

  • Comprehensive workflow: Assess 15 genes with one simple workflow instead of single, iterative gene testing with polymerase chain reaction (PCR)
  • Efficient: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
  • Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1,2, key opinion leaders3,4, and pharmaceutical research
  • Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples
TruSight Tumor 15 Sample Datasets

3 human reference samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.




TruSight Tumor 15 Data Sheet | PDF(< 1 MB)


Visit  illumina logo  Web Site...

Comments (0)
No customer reviews for the moment.